Similarly, phase I dose-escalation trials with the CD123-CD3 targeting BiTE XmAb14045 and the dual-afffity retargeting (DART) antibody flotetuzumab showed promising anti-leukemia activity in heavily treated relapsed refractory AML patients, with manageable toxicities. This evidence concerns the gene IL3RA and acute myeloid leukemia.